Who is sponsoring NCT05108194?

NCT05108194 is sponsored by University of Missouri, St. Louis.

What drugs are being tested in NCT05108194?

Interventions in NCT05108194: SMS Personalized Sleep Intervention.

What condition does NCT05108194 study?

NCT05108194 studies Insomnia, Sleep Disorder.

Is NCT05108194 still recruiting?

NCT05108194 is currently status unknown. Last updated 25 April 2022.

Last reviewed 2022-04-25 · How we verify

NCT05108194

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of a Personalized SMS Intervention for Insomnia

Status unknown EARLY_PHASE1 Last updated 25 April 2022

What this trial tests

EARLY_PHASE1 trial testing SMS Personalized Sleep Intervention in Insomnia in 50 participants. Status unknown.

Timeline

15 November 2021

Primary endpoint
1 June 2022

1 June 2022

Quick facts

Lead sponsor	University of Missouri, St. Louis
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	15 November 2021
Primary completion	1 June 2022
Estimated completion	1 June 2022
Sites	1 location across United States

Drugs / interventions tested

SMS Personalized Sleep Intervention

Conditions studied

Insomnia — all drugs for Insomnia →
Sleep Disorder — all drugs for Sleep Disorder →

Sponsor

University of Missouri, St. Louis

Who can join

18 and older, any sex, with Insomnia or Sleep Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this research is to establish a proof of concept for optimizing and evaluating a personalized SMS intervention based for individuals with chronic sleep problems.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Insomnia

Currently open trials in the same condition.

NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting
NCT07071324 — CF Wellness Program · NA · recruiting
NCT07417813 — A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders · recruiting
NCT06348082 — Project Women's Insomnia Sleep Health Equity Study (WISHES) · NA · recruiting

Other University of Missouri, St. Louis trials

Trials by the same sponsor.

NCT04304378 — Trauma Informed Treatment Algorithms for Novel Outcomes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05108194 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Missouri, St. Louis
Last refreshed: 25 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05108194.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing